AU5441199A - Oral vaccine compositions - Google Patents

Oral vaccine compositions

Info

Publication number
AU5441199A
AU5441199A AU54411/99A AU5441199A AU5441199A AU 5441199 A AU5441199 A AU 5441199A AU 54411/99 A AU54411/99 A AU 54411/99A AU 5441199 A AU5441199 A AU 5441199A AU 5441199 A AU5441199 A AU 5441199A
Authority
AU
Australia
Prior art keywords
microparticles
oral vaccine
vaccine formulations
less
vaccine compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54411/99A
Other languages
English (en)
Inventor
David James Brayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of AU5441199A publication Critical patent/AU5441199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU54411/99A 1998-09-01 1999-08-31 Oral vaccine compositions Abandoned AU5441199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9875998P 1998-09-01 1998-09-01
US60098759 1998-09-01
PCT/IE1999/000086 WO2000012124A1 (en) 1998-09-01 1999-08-31 Oral vaccine compositions

Publications (1)

Publication Number Publication Date
AU5441199A true AU5441199A (en) 2000-03-21

Family

ID=22270760

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54411/99A Abandoned AU5441199A (en) 1998-09-01 1999-08-31 Oral vaccine compositions

Country Status (7)

Country Link
EP (2) EP1107782B1 (enExample)
JP (1) JP4601823B2 (enExample)
AT (1) ATE452651T1 (enExample)
AU (1) AU5441199A (enExample)
CA (1) CA2341352C (enExample)
DE (1) DE69941848D1 (enExample)
WO (1) WO2000012124A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
AU2003230692A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
FR2857592B1 (fr) * 2003-07-18 2006-02-24 Sod Conseils Rech Applic Nouveau procede de preparation de microparticules
ES2396240T3 (es) * 2005-04-20 2013-02-20 Mitsuru Akashi Poliaminoácido para usar como adyuvante
JP4621218B2 (ja) * 2007-02-09 2011-01-26 有限会社バイオ研 Ｔｈ１誘導剤及びその製造方法
WO2011026111A1 (en) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
DK0515415T3 (da) * 1990-02-12 1995-11-27 Smithkline Beecham Biolog Hidtil ukendt vaccine og fremgangsmåde til fremstilling deraf
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
KR100291357B1 (ko) 1993-01-08 2001-09-17 터베이 피터. 백신제제
AU7979094A (en) 1993-10-22 1995-05-08 Genentech Inc. Methods and compositions for microencapsulation of adjuvants
WO1995017167A1 (de) 1993-12-23 1995-06-29 Gff Gesellschaft Zur Förderung Der Industrieorientierten Forschung Verfahren zur potenzierung der immunologischen antwort
JP3747077B2 (ja) * 1994-04-28 2006-02-22 武田薬品工業株式会社 百日咳菌由来感染防御成分の分離取得方法
AU4755696A (en) * 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines

Also Published As

Publication number Publication date
DE69941848D1 (de) 2010-02-04
EP1107782A1 (en) 2001-06-20
EP2168593A1 (en) 2010-03-31
ATE452651T1 (de) 2010-01-15
JP2002523470A (ja) 2002-07-30
JP4601823B2 (ja) 2010-12-22
CA2341352A1 (en) 2000-03-09
CA2341352C (en) 2013-01-08
WO2000012124A1 (en) 2000-03-09
EP1107782B1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
AU5441199A (en) Oral vaccine compositions
CA2171844A1 (en) Sustained release formulations for 24 hour release of metoprolol
CA2266403A1 (en) Stable photoprotective compositions
FI935396A7 (fi) Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta
EP0965343A3 (en) Ziprasidone formulations
GB9725084D0 (en) Vaccine compositions
HU9501554D0 (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
CA2217178A1 (en) Vaccines containing a saponin and a sterol
WO1997001640A3 (en) Vaccines against hepatitis c
WO1998034587A8 (en) Oral composition exhibiting enhance uptake
CA2096529A1 (en) Recombinant avirulent salmonella antifertility vaccines
AU5441299A (en) Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
CA2177668A1 (en) Mammalian vaccine compositions comprising squalene or squalane, glycerol and a surfactant as an adjuvant
AU2472888A (en) Method of solidification and encapsulation using core-shell polymer particles
AU635049B2 (en) Encapsulation method, microelectronic devices made therefrom, and heat curable compositions
CA2347195A1 (en) Oral pharmaceutical compositions containing buprenorphin
PH30098A (en) 4,13-dioxabicyclo¬8.2.1¾ tridecenone compounds and pharmaceutical compositions containing them
JP2002523471A5 (enExample)
GB2336592B (en) Polymer for photoresist,photoresist composition containing the same,and preparation method thereof
ZA971746B (en) Taxoids, their preparation and pharmaceutical compositions containing them.
AU7230194A (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
AU6097499A (en) Light stabilisation method for sunscreens derived from 1,3,5-triazine
WO2003059331A3 (en) Medicinal aerosol compositions with an amide and/or ester containing excipient compound
WO1999013916A3 (en) Methods and compositions for medical imaging
EP0804923A3 (en) Skin protection, fragrance enhancing and vitamin delivery composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase